Literature DB >> 2949284

[Effectiveness and tolerance of piperacillin in 333 patients].

Y Mouton, C Beuscart, C Soussy.   

Abstract

In a French multicentric trial the effectiveness and safety of piperacillin were evaluated in 333 patients with severe infections. Piperacillin was administered alone in 212 cases. The overall results show that the drug was clinically effective in 85% of the patients. The results of this French study are similar to those of other studies previously published. They demonstrate an increase in the number of failures against ampicillin-resistant and carbenicillin-resistant strains, even when these strains were sensitive to piperacillin in vitro. Piperacillin was tolerated as well as the other beta-lactam antibiotics, the main side-effects being hypersensitivity reactions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2949284

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  4 in total

1.  Definition and determination of in vitro antibiotic susceptibility breakpoints for bacteria in France. The Comité de l'Antibiogramme de la Société Française de Microbiologie.

Authors:  C J Soussy; R Cluzel; P Courvalin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-03       Impact factor: 3.267

2.  Mechanism of suppression of piperacillin resistance in enterobacteria by tazobactam.

Authors:  T A Kadima; J H Weiner
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

3.  Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia.

Authors:  R Speich; E Imhof; M Vogt; M Grossenbacher; W Zimmerli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-05       Impact factor: 3.267

4.  Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections.

Authors:  J L Fournier; F Ramisse; A C Jacolot; M Szatanik; O J Petitjean; J M Alonso; M R Scavizzi
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.